Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3369
Name Ewing sarcoma
Definition A connective tissue cancer that has_material_basis_in neural crest cells derives_from undeveloped, undifferentiated neuroectoderm.
Source DiseaseOntology.org
Alt Ids DOID:4392 DOID:4390 DOID:0050607 DOID:4980 DOID:4158 DOID:4391
Path disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer Ewing sarcoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Ponatinib Ewing sarcoma predicted - sensitive detail...
MLH1 negative Pembrolizumab Ewing sarcoma sensitive detail...
MSH6 negative Pembrolizumab Ewing sarcoma sensitive detail...
PIK3CA mutant Irinotecan + Temozolomide + Temsirolimus Ewing sarcoma predicted - sensitive detail...
PIK3CA mutant Temsirolimus Ewing sarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00020566 Phase III Busulfan + Melphalan Dactinomycin + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status USA | NZL | CAN | AUS 1
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status USA 0
NCT00089245 Phase I Omburtamab I-131 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Terminated USA 0
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT01241162 Phase I Decitabine Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma Completed USA 0
NCT01286987 Phase I Talazoparib Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors Completed USA | GBR 0
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed USA 0
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting CAN 0
NCT01661400 Phase I Cyclophosphamide Thalidomide Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors Completed USA 0
NCT01858168 Phase I Olaparib + Temozolomide Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma Active, not recruiting USA 0
NCT01946529 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Bevacizumab + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Sorafenib + Temozolomide + Temsirolimus + Vincristine Sulfate Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors Active, not recruiting USA 0
NCT02013336 Phase I Cyclophosphamide + Liposomal irinotecan Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors Unknown status USA 0
NCT02044120 Phase I Niraparib + Temozolomide ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma Completed USA | GBR 0
NCT02048371 Phase II Regorafenib A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas Completed USA 0
NCT02100891 Phase II Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors Completed USA 0
NCT02116777 Phase Ib/II Talazoparib + Temozolomide BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Completed USA 0
NCT02173093 Phase Ib/II Aldesleukin + GD2Bi-aATC + Sargramostim Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma Unknown status USA 0
NCT02306161 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Ganitumab Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting USA | CAN 1
NCT02454972 Phase II Lurbinectedin Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed USA | SWE | ITA | GBR | FRA | ESP | DEU | CHE | BEL 0
NCT02601950 Phase II Tazemetostat A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Completed USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS 1
NCT02644460 Phase I Abemaciclib Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Completed USA 0
NCT02657005 Phase I TK216 TK216 in Patients With Relapsed or Refractory Ewing Sarcoma Terminated USA 0
NCT02748135 Phase Ib/II TB-403 A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma Completed USA 0
NCT02789228 Phase I MultiTAA-specific T cells Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) Active, not recruiting USA 0
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT02890758 Phase I Nogapendekin alfa inbakicept Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT02982941 Phase I MGA271 Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors Completed USA 0
NCT03139331 Phase I Irinotecan + Pazopanib + Temozolomide PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma Completed USA 0
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT03190174 Phase Ib/II Nab-rapamycin + Nivolumab Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma Completed USA 0
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213678 Phase II LY3023414 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Unknown status USA 0
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Completed USA 1
NCT03245151 Phase Ib/II Everolimus + Lenvatinib Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors Completed USA | CAN 0
NCT03441360 Phase II Eribulin Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) Completed USA 0
NCT03458728 Phase Ib/II Copanlisib Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients Terminated USA 0
NCT03495921 Phase III FANG vaccine + Irinotecan + Temozolomide Irinotecan + Temozolomide Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA) Terminated USA 0
NCT03514407 Phase I INCB059872 A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma Terminated USA | ITA | GBR | ESP 0
NCT03585465 Phase Ib/II Capecitabine + Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Cyclophosphamide + Vinblastine Cyclophosphamide + Nivolumab + Vinblastine Capecitabine + Nivolumab Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors Active, not recruiting FRA | BEL 0
NCT03600649 Phase I Seclidemstat Clinical Trial of SP-2577 in Patients With Relapsed or Refractory Ewing Sarcoma Active, not recruiting USA 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03709680 Phase I Irinotecan + Palbociclib + Temozolomide Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors Active, not recruiting USA | TUR | SWE | SVK | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | ARG 2
NCT03778996 Phase II Methoxsalen + Phenytoin + Sirolimus + SM88 SM-88 as Maintenance Therapy for Advanced Ewing's Sarcoma Patients and as Salvage Therapy for Sarcoma Patients (HopES) Active, not recruiting USA 0
NCT03880123 Phase I Ixazomib + Selinexor Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma Withdrawn USA 0
NCT04067115 Phase Ib/II Irinotecan + Trabectedin SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients (U01CA236220) Active, not recruiting USA 0
NCT04129151 Phase II Ganitumab + Palbociclib Palbociclib + Ganitumab In Ewing Sarcoma Terminated USA 0
NCT04183062 Phase II BIO-11006 + Docetaxel + Gemcitabine BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases Withdrawn USA 0
NCT04205227 Phase Ib/II ENB003 + Pembrolizumab ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors Active, not recruiting USA | AUS 0
NCT04469530 Phase II Celecoxib + Cyclophosphamide + Etoposide + Sirolimus Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) Recruiting USA 0
NCT04544995 Phase I Dostarlimab-gxly + Niraparib Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors Recruiting HUN | GBR | FRA | ESP | DEU | CZE 0
NCT04593758 Phase Ib/II CPI-613 + Hydroxychloroquine To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613 (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue Completed USA 0
NCT04661852 Phase I Cabozantinib + Cyclophosphamide + Pegfilgrastim + Topotecan Cabozantinib + Cyclophosphamide + Filgrastim + Topotecan Cabozantinib With Topotecan-Cyclophosphamide Completed USA 0
NCT04851119 Phase Ib/II BC2059 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Recruiting USA 0
NCT04890093 Phase Ib/II STA-8666 + Temozolomide + Vincristine Sulfate Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors Recruiting USA 0
NCT04901702 Phase Ib/II Irinotecan + Temozolomide Irinotecan + Talazoparib Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Active, not recruiting USA | CAN 0
NCT04906876 Phase II Docetaxel + Elraglusib + Gemcitabine 9-ING-41Combined With Chemotherapy in Adolescents and Adults Withdrawn USA 0
NCT05064306 Expanded access Omburtamab I-131 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults Available USA 0
NCT05071209 Phase Ib/II Elimusertib Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Active, not recruiting USA | CAN 0
NCT05093322 Phase Ib/II Gemcitabine + Surufatinib A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Completed USA 0
NCT05116800 Phase II Docetaxel + Elraglusib + Gemcitabine Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma Withdrawn USA 0
NCT05131386 Phase II Dexamethasone + Trabectedin Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) Recruiting ESP 0
NCT05135975 Phase II Cabozantinib A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors Recruiting USA 0
NCT05182164 Phase II Cabozantinib + Pembrolizumab Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (PEMBROCABOSARC) Recruiting FRA 0
NCT05253131 Phase Ib/II AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas Not yet recruiting USA 0
NCT05275426 Phase II Gemcitabine + LY2880070 A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor Recruiting USA 0
NCT05302921 Phase II Ipilimumab + Nivolumab Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors Active, not recruiting USA 0
NCT05389462 Phase I ADCT-601 + Gemcitabine ADCT-601 A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors Recruiting USA | GBR | FRA | ESP 0
NCT05440786 Phase II Irinotecan + Temozolomide Abemaciclib + Irinotecan + Temozolomide CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma Recruiting USA | ITA | FRA | ESP | DEU | AUS 1
NCT05605522 Phase I 225Ac-FPI-2059 A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours Recruiting USA | AUS 0
NCT05830084 Phase I Cyclophosphamide + Etoposide + Ifosfamide + Regorafenib + Vincristine Sulfate Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Regorafenib + Vincristine Sulfate Busulfan + Melphalan Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma (REGO-EWING) Recruiting FRA 0
NCT05841563 Phase I PM54 Clinical Trial of PM54 in Advanced Solid Tumors Patients. Recruiting USA | ESP | BEL 0
NCT05918640 Phase Ib/II Lurbinectedin Lurbinectedin in FET-Fused Tumors (LiFFT) Recruiting USA 0
NCT05968768 Phase II Naxitamab To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly) Recruiting POL 0
NCT06094101 Phase Ib/II Peptide vaccine IPX Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) (PerVision) Recruiting DEU 0
NCT06156410 Phase I Cabozantinib + Ifosfamide Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma Recruiting USA 0
NCT06395103 Phase Ib/II VLS-101 Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) Recruiting USA | ISR | GBR | ESP | BRA 2
NCT06541262 Phase Ib/II Irinotecan + Silmitasertib + Temozolomide + Vincristine Sulfate Irinotecan + Silmitasertib + Temozolomide Silmitasertib (CX-4945) in Combination with Chemotherapy for Relapsed Refractory Solid Tumors Recruiting USA 0
NCT06566092 Phase I Lifileucel LN-145 Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants Recruiting USA 0